Eizen Joshua M 4

What Happened
Joshua M. Eizen, Chief Operating Officer and Chief Legal Officer of AN2 Therapeutics (ANTX), disposed of 5,945 shares on July 8, 2026 at $4.17 per share for a reported total of $24,803. The sale was made pursuant to the terms of a grant to satisfy tax withholding obligations arising from RSUs that vested on July 1, 2026 — a routine, tax-related sale rather than an open-market investment decision.

Key Details

• Transaction date and price: 2026-07-08, sale at $4.17 per share (total $24,803).
• Shares disposed: 5,945 (transaction code S = Sale).
• Reason for sale: Footnote F1 — sale to satisfy tax withholding on RSU vesting (code F = tax withholding).
• Shares owned after transaction: not specified in the provided excerpt; filing notes an adjusted total that includes a 5,000-share ESPP purchase on 2026-03-31 (Footnote F3).
• RSU balance/vesting (Footnote F2): includes 170,000 RSUs across four grants — 30,000 (vesting from 1/1/2024), 31,500 (from 11/4/2024), 58,500 (from 1/1/2025) and 50,000 (from 1/1/2026) — each vesting 1/4 annually over four years, subject to continued service.
• Timeliness: filing does not indicate a late report.

Context
Sales made specifically to cover tax withholding on vested RSUs are common and typically routine; they do not necessarily indicate negative views about the company. For retail investors, outright purchases or large discretionary sales are generally more informative about insider sentiment. This filing mainly documents equity compensation vesting and the routine tax-related disposition of a portion of those shares.